TY  - BOOK
AU  - Bhatt, Meghna
AU  - Kazi, Sadaf
AU  - Smith, D Max
AU  - Swain, Sandra M
TI  - Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives
SN  - 1462-2416
PY  - 2023///
KW  - *Pharmacogenetics
KW  - *Pharmacogenomic Testing
KW  - Humans
KW  - Medical Oncology
KW  - Pharmacogenetics/ed [Education]
KW  - MedStar Institute for Innovation
KW  - MedStar Washington Hospital Center
KW  - Associate Dean for Research Development
KW  - MedStar Health
KW  - National Center for Human Factors in Healthcare
KW  - Pharmacogenomics
KW  - Pharmacy Residency
KW  - Journal Article
N2  - Aim: Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. Materials & methods: A questionnaire was designed and disseminated to 71 practicing oncology providers across the MedStar Health System. Results: 25 of 70 (36%) eligible oncology providers were included. 88% were aware of PGx testing and 72% believed PGx can improve care. Of providers who had ordered a medication with PGx implications in the past month, interest in PGx for anticancer (90-100%) and supportive care medications (>75%) was high. Providers with previous PGx education were more likely to have ordered a test (odds ratio: 7.9; 95% CI: 1.1-56; p = 0.0394). Conclusion:  Oncology provider prescribing practices and interest in PGx suggest opportunities for implementation
UR  - https://dx.doi.org/10.2217/pgs-2023-0164
ER  -